BeOne Medicines (NASDAQ:ONC) Price Target Raised to $396.00 at Citizens Jmp

BeOne Medicines (NASDAQ:ONC) had its target price hoisted by stock analysts at Citizens Jmp from $348.00 to $396.00 in a research note issued on Friday,Benzinga reports. The firm currently has a “market outperform” rating on the stock. Citizens Jmp’s price target would indicate a potential upside of 24.81% from the stock’s current price.

ONC has been the subject of several other reports. Barclays started coverage on BeOne Medicines in a research note on Thursday, September 18th. They set an “overweight” rating and a $385.00 price objective for the company. Royal Bank Of Canada upped their price objective on shares of BeOne Medicines from $349.00 to $364.00 and gave the stock an “outperform” rating in a research report on Thursday, August 7th. Zacks Research downgraded shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 28th. Wall Street Zen raised shares of BeOne Medicines from a “buy” rating to a “strong-buy” rating in a report on Friday, October 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $350.18.

BeOne Medicines Stock Down 4.5%

Shares of BeOne Medicines stock traded down $15.07 during trading hours on Friday, hitting $317.29. The company had a trading volume of 35,843 shares, compared to its average volume of 389,623. The company has a market cap of $34.79 billion, a P/E ratio of -183.40 and a beta of 0.31. BeOne Medicines has a twelve month low of $170.99 and a twelve month high of $355.30. The company’s 50-day moving average is $326.63 and its two-hundred day moving average is $287.14. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.95 and a quick ratio of 1.72.

BeOne Medicines (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, November 6th. The company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.37. The firm had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.34 billion. BeOne Medicines had a negative net margin of 3.89% and a negative return on equity of 1.22%. BeOne Medicines has set its FY 2025 guidance at EPS. Analysts anticipate that BeOne Medicines will post -5.82 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other BeOne Medicines news, insider Titus B. Ball sold 122 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $326.76, for a total value of $39,864.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John Oyler sold 27,803 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $325.71, for a total transaction of $9,055,715.13. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 157,074 shares of company stock valued at $49,396,898. Insiders own 6.62% of the company’s stock.

Hedge Funds Weigh In On BeOne Medicines

Large investors have recently modified their holdings of the company. Anchor Investment Management LLC acquired a new position in BeOne Medicines during the second quarter valued at approximately $26,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of BeOne Medicines in the second quarter valued at $28,000. Daiwa Securities Group Inc. acquired a new stake in BeOne Medicines during the 2nd quarter valued at $35,000. Farther Finance Advisors LLC purchased a new stake in BeOne Medicines during the 2nd quarter worth $39,000. Finally, Signaturefd LLC acquired a new position in BeOne Medicines in the 2nd quarter worth $49,000. 48.55% of the stock is currently owned by hedge funds and other institutional investors.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.